Gyre Therapeutics Inc (GYRE)

$11.50 +0.67 (6.19%)
Market Cap 893.37M
Revenue (ttm) 105.76M
Net Income (ttm) 12.09M
EPS (ttm) N/A
PE Ratio 118.50
Forward PE 22.57
Profit Margin 11.43%
Debt to Equity Ratio 0.00
Volume 165,100
Avg Vol 176,832
Day's Range N/A - N/A
Shares Out 93.74M
Stochastic %K 71%
Beta 1.90
Analysts Strong Sell
Price Target $20.00

Latest News on GYRE

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 6:00 AM EDT - 5 days ago

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Mar 31, 2025, 7:00 AM EDT - 6 weeks ago

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Mar 27, 2025, 7:00 AM EDT - 6 weeks ago

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 17, 2025, 4:15 PM EDT - 2 months ago

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Nov 13, 2024, 6:00 AM EST - 6 months ago

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Oct 22, 2024, 4:05 PM EDT - 7 months ago

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Oct 1, 2024, 4:05 PM EDT - 8 months ago

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Aug 13, 2024, 6:00 AM EDT - 9 months ago

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Aug 9, 2024, 7:00 AM EDT - 9 months ago

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Jul 2, 2024, 4:05 PM EDT - 11 months ago

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Jun 18, 2024, 4:05 PM EDT - 11 months ago

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

May 30, 2024, 4:05 PM EDT - 1 year ago

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

May 28, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:10 PM EDT - 1 year ago

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 26, 2024, 6:00 AM EDT - 1 year ago

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Dec 15, 2023, 9:04 AM EST - 1 year ago

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

Nov 13, 2023, 7:00 AM EST - 1 year ago

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting